評論
打印
Chief Executive of Pfizer Pharmaceuticals, Ian Read, has been obsessed with finding a tax “inversion” deal for at least two years.
至少在過去兩年，輝瑞首席執行官伊恩·瑞德一直對促成“稅負倒置”情有獨鐘。
He tried AstraZeneca but lost the takeover bid in an embarrassing fashion.
輝瑞曾對阿斯利康表示收購意向，但卻尷尬收場。
Then, he tried to acquire GlaxoSmithKline, but got nowhere.
隨后又向葛蘭素史克伸出橄欖枝，但最終無果。
Now he’s landed on Allergan, the Botox firm that is the biggest Irish company that nobody knew was Irish.
如今又中意肉毒桿菌生產商艾爾建，艾爾建是愛爾蘭最大制藥公司，但卻沒人知道他們來自愛爾蘭。
Pfizer anticipates that the combined company will have an adjusted effective tax rate of approximately 17%-18%.
據輝瑞預計，新公司稅率預計下調至17%-18%。
That’s the logic of the deal a previous 26% tax rate that falls to close to 17%.
之前的26%稅率也有望下調至近17%。
譯文屬可可英語原創，未經允許，不得轉載。
